Get started
Work

1892P A pooled meta-analysis of salvage nivolumab/ipilimumab (N+I) after nivolumab (N) in patients with advanced renal cell carcinoma (RCC)

Year: 2023
Type: review
Study design: Systematic Review
DOI: 10.1016/j.annonc.2023.09.1122
Authors: R.R. McKay, W. Xie, K. Leucht, O. Jegede, D.A. Braun, M.B. Atkins, M-O. Grimm, T.K. Choueiri
Institutions: University of California San Diego, Dana-Farber Cancer Institute, Jena University Hospital, Yale Cancer Center, Yale University, Georgetown University, Georgetown Lombardi Comprehensive Cancer Center
Language: English
Field: Medicine
Open Access status: bronze
Funders: Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, American Society of Clinical Oncology, Intuitive Surgical, Exelixis, Society for Immunotherapy of Cancer, Seagen, Eisai, Deutsche Gesellschaft für Urologie, European Society for Medical Oncology, Institut Gustave-Roussy, Ipsen, AIO-Studien, EUSA Pharma, Aptitude Health, Genentech, EMD Serono, Cilag
OpenAlex ID: W4387826035
FWCI:
Cites:
Cited by:
Related to: 10